Trial of aciclovir in the prophylaxis of herpes infections in critical care

Not Applicable

Completed

• Conditions: Herpes simplex virus infection of the lower respiratory tract in critically ill patients; Infections and Infestations; Herpes simplex virus

• Registration Number: ISRCTN29934637
• Lead Sponsor: Greater Glasgow Health Board (North Glasgow University Hospitals Division) (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-03-14
• Study Completion: 2009-09-30
• Last Update Posted: 30 May 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. All patients 18 years or over entering ICU
2. Patient expected to stay in the ICU longer than 36 hours and intubated with an endotracheal or tracheostomy tube within 24 hours of admission to ICU
3. Patient not requiring treatment with aciclovir, valaciclovir, ganciclovir, foscarnet, probenicid or other drug known to have anti-herpes simplex activity
4. Patient must have no known allergy to aciclovir
5. Females of childbearing age must have negative pregnancy test on admission
6. Written informed consent from the patient or assent obtained from relatives

Exclusion Criteria

1. Duration of admission confidently expected to be less than 36 hours
2. Patients with endotracheal or tracheostomy tube placed more than 24 hours before admission to ICU
3. Patient has clinical features of HSV disease
4. Patient previously randomised to this study
5. Patients deemed to be suitable for entry to another trial
6. Previous hypersensitivity to aciclovir or valaciclovir
7. Patient requiring agent with anti-herpes virus activity
8. Patient previously enrolled in another trial of an investigational drug within the past 30 days
9. Patient is pregnant or lactating

Study & Design

• Study Type: Interventional
• Study Design: Not specified